{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:39:31Z","timestamp":1787009971704,"version":"build-2736575974"},"reference-count":152,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>More than 90% of pregnant women take at least one drug during pregnancy. Drug dose adjustments during pregnancy are sometimes necessary due to various pregnancy-induced physiological alterations frequently associated with lower plasma concentrations. However, the clinical relevance or benefits of therapeutic drug monitoring (TDM) in pregnant women have not been specifically studied. Clinical pharmacokinetic studies in pregnant women are incredibly challenging for many reasons. Despite this, regulatory agencies have made efforts to encourage the inclusion of this population in clinical trials to achieve more information on the pharmacotherapy of pregnant women. This review aims to provide support for TDM recommendations and dose adjustments in pregnant women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The search was conducted after a predetermined strategy on PubMed and Scopus databases using the MeSH term \u201cpregnancy\u201d alongside other terms such as \u201cPregnancy and dose adjustment,\u201d \u201cPregnancy and therapeutic drug monitoring,\u201d \u201cPregnancy and PBPK,\u201d \u201cPregnancy and pharmacokinetics,\u201d and \u201cPregnancy and physiological changes.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The main information on TDM in pregnant women is available for antiepileptics, antipsychotics, antidepressants, antibiotics, antimalarials, and oncologic and immunosuppressive drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>More data are needed to support informed benefit\u2013risk decision making for the administration of drugs to pregnant women. TDM and\/or pharmacokinetic studies could ensure that pregnant women receive an adequate dosage of an active drug. Mechanistic modeling approaches potentially could increase our knowledge about the pharmacotherapy of this special population, and they could be used to better design dosage regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001039","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:29Z","timestamp":1663718429000},"page":"159-172","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Optimizing Therapeutic Drug Monitoring in Pregnant Women: A Critical Literature Review"],"prefix":"10.1097","volume":"45","author":[{"given":"Fernanda de Lima","family":"Moreira","sequence":"first","affiliation":[{"name":"Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhohann Richard de Lima","family":"Benzi","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus de Lucca","family":"Thomaz","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldo","family":"Duarte","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0074-4953","authenticated-orcid":false,"given":"Vera Lucia","family":"Lanchote","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2011.02.029","article-title":"Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008","volume":"205","author":"Mitchell","year":"2011","journal-title":"Am J Obstet Gynecol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/cid\/ciz121","article-title":"Importance of prospective studies in pregnant and breastfeeding women living with human immunodeficiency virus","volume":"69","author":"Colbers","year":"2019","journal-title":"Clin Infect Dis."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0b013e3181a6b325","article-title":"Practice parameter update: management issues for women with epilepsy\u2013focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and American Epilepsy Society","volume":"73","author":"Harden","year":"2009","journal-title":"Neurology"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"151226","DOI":"10.1016\/j.semperi.2020.151226","article-title":"Task force on research specific to pregnant and lactating women","volume":"44","author":"Byrne","year":"2020","journal-title":"Semin Perinatol."},{"issue":"suppl 2","key":"R9-20250603","first-page":"S18","article-title":"The importance of clinical research in pregnant women to inform prescription drug labeling","volume":"60","author":"Dinatale","year":"2020","journal-title":"J Clin Pharmacol."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/cpt.2212","article-title":"Assuring access to safe medicines in pregnancy and breastfeeding","volume":"110","author":"Nooney","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10928-020-09711-2","article-title":"Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy","volume":"47","author":"Abduljalil","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cpt.2048","article-title":"Optimizing pharmacology studies in pregnant and lactating women using lessons from HIV: a consensus statement","volume":"110","author":"Eke","year":"2020","journal-title":"Clin Pharmacol Ther."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/hiv.12252","article-title":"Pharmacokinetics of tenofovir during pregnancy and postpartum","volume":"16","author":"Best","year":"2015","journal-title":"HIV Med."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/cid\/civ366","article-title":"Raltegravir in HIV-1-infected pregnant women: pharmacokinetics, safety, and efficacy","volume":"61","author":"Blonk","year":"2015","journal-title":"Clin Infect Dis."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/QAD.0000000000001755","article-title":"Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV","volume":"32","author":"Mulligan","year":"2018","journal-title":"AIDS"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"461731","DOI":"10.1016\/j.chroma.2020.461731","article-title":"A review of recent advances in microsampling techniques of biological fluids for therapeutic drug monitoring","volume":"1635","author":"Tey","year":"2021","journal-title":"J Chromatogr A"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"e02168","DOI":"10.1128\/AAC.02168-20","article-title":"Population pharmacokinetics of tenofovir in pregnant and postpartum women using tenofovir disoproxil fumarate","volume":"65","author":"Eke","year":"2021","journal-title":"Antimicrob Agents Chemother."},{"issue":"suppl 1","key":"R20-20250603","first-page":"S63","article-title":"Model-informed dose optimization in pregnancy","volume":"60","author":"Chaphekar","year":"2020","journal-title":"J Clin Pharmacol."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/psp4.12551","article-title":"Pharmacokinetic characterization to enable medicine use in pregnancy, the potential role of physiologically-based pharmacokinetic modeling: a regulatory perspective","volume":"9","author":"Cole","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s40262-020-00962-3","article-title":"Dose adjustment of quetiapine and aripiprazole for pregnant women using physiologically based pharmacokinetic modeling and simulation","volume":"60","author":"Zheng","year":"2021","journal-title":"Clin Pharmacokinet."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"e01315","DOI":"10.1002\/brb3.1315","article-title":"Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy","volume":"9","author":"Ding","year":"2019","journal-title":"Brain Behav."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.dmpk.2015.05.002","article-title":"Polymorphisms of ABCG2, ABCB1 and HNF4\u03b1 are associated with lamotrigine trough concentrations in epilepsy patients","volume":"30","author":"Zhou","year":"2015","journal-title":"Drug Metab Pharmacokinet."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/clpt.1987.193","article-title":"Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans","volume":"42","author":"Cohen","year":"1987","journal-title":"Clin Pharmacol Ther."},{"key":"R27-20250603","first-page":"S336","article-title":"Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant, topiramate in healthy men","volume":"11","author":"Wu","year":"1994","journal-title":"Pharm Res."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF03190614","article-title":"Metabolism and excretion of the antiepileptic\/antimigraine drug, Topiramate in animals and humans","volume":"30","author":"Caldwell","year":"2005","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1528-1167.2008.01776.x","article-title":"Serum concentration\/dose ratio of topiramate during pregnancy","volume":"50","author":"Westin","year":"2009","journal-title":"Epilepsia"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects","volume":"16","author":"Johannessen Landmark","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0074-7742(08)00013-5","article-title":"Antiepileptic drug therapy in pregnancy I: gestation-induced effects on AED pharmacokinetics","volume":"83","author":"Pennell","year":"2008","journal-title":"Int Rev Neurobiol."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1528-1157.1994.tb02921.x","article-title":"Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin","volume":"35","author":"Tomson","year":"1994","journal-title":"Epilepsia"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/WCO.0b013e32832923d7","article-title":"Managing antiepileptic drugs during pregnancy and lactation","volume":"22","author":"Sabers","year":"2009","journal-title":"Curr Opin Neurol."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1212\/WNL.0000000000006240","article-title":"Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy","volume":"91","author":"Voinescu","year":"2018","journal-title":"Neurology"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.eplepsyres.2009.01.011","article-title":"Seizure deterioration in women treated with oxcarbazepine during pregnancy","volume":"84","author":"Petrenaite","year":"2009","journal-title":"Epilepsy Res."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","article-title":"Overview of the clinical pharmacokinetics of oxcarbazepine","volume":"24","author":"Flesch","year":"2004","journal-title":"Clin Drug Invest."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eplepsyres.2018.05.002","article-title":"Zonisamide serum concentrations during pregnancy","volume":"144","author":"Reimers","year":"2018","journal-title":"Epilepsy Res."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1528-1167.2007.00983.x","article-title":"Pharmacokinetics and drug interactions with zonisamide","volume":"48","author":"Sills","year":"2007","journal-title":"Epilepsia"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cpt.770","article-title":"Treatment with antipsychotics in pregnancy: changes in drug disposition","volume":"103","author":"Westin","year":"2018","journal-title":"Clin Pharmacol Ther."},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"e015738","DOI":"10.1136\/bmjopen-2016-015738","article-title":"Changes in drug disposition of lithium during pregnancy: a retrospective observational study of patient data from two routine therapeutic drug monitoring services in Norway","volume":"7","author":"Westin","year":"2017","journal-title":"BMJ Open"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.12740\/PP\/65307","article-title":"Therapeutic drug monitoring of atypical antipsychotics","volume":"51","author":"Urban","year":"2017","journal-title":"Psychiatr Pol."},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.4155\/bio.15.123","article-title":"Current advances in biosampling for therapeutic drug monitoring of psychiatric CNS drugs","volume":"7","author":"Mercolini","year":"2015","journal-title":"Bioanalysis"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bcp.13480","article-title":"Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation","volume":"84","author":"Polasek","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JCP.0000000000000087","article-title":"Pharmacotherapy for mood disorders in pregnancy","volume":"34","author":"Deligiannidis","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13318-017-0421-2","article-title":"Population pharmacokinetic analyses of lithium: a systematic review","volume":"43","author":"Methaneethorn","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/17425255.2019.1669560","article-title":"Pharmacokinetic considerations for current state-of-the-art antidepressants","volume":"15","author":"Wyska","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"231","DOI":"10.31887\/DCNS.2005.7.3\/pbaumann","article-title":"The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants","volume":"7","author":"Baumann","year":"2005","journal-title":"Dialogues Clin Neurosci."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"110228","DOI":"10.1016\/j.pnpbp.2020.110228","article-title":"Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: a systematic review & combined analysis","volume":"107","author":"Schoretsanitis","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41540-020-00157-3","article-title":"Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy","volume":"6","author":"George","year":"2020","journal-title":"NPJ Syst Biol Appl."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/schbul\/sbn107","article-title":"Antipsychotic therapy during early and late pregnancy. A systematic review","volume":"36","author":"Gentile","year":"2010","journal-title":"Schizophrenia Bull."},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00737-013-0330-6","article-title":"Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585, 615 deliveries","volume":"16","author":"Toh","year":"2013","journal-title":"Arch Womens Ment Health"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/AOG.0000000000000759","article-title":"Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy","volume":"125","author":"Coughlin","year":"2015","journal-title":"Obstet Gynecol."},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1176\/appi.ps.201600408","article-title":"Antipsychotic medication use among publicly insured pregnant women in the United States","volume":"68","author":"Park","year":"2017","journal-title":"Psychiatr Serv."},{"key":"R58-20250603","first-page":"17","article-title":"Maternal and infant pharmacokinetics of psychotropic medications during pregnancy and lactation","author":"Kokras","year":"2019"},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions","volume":"9","author":"Urichuk","year":"2008","journal-title":"Curr Drug Metab."},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jphp.13236","article-title":"Quetiapine dose optimisation during gestation: a pharmacokinetic modelling study","volume":"72","author":"Badhan","year":"2020","journal-title":"J Pharm Pharmacol."},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2125.2000.00151.x","article-title":"Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions","volume":"49","author":"Prakash","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-0033-1347176","article-title":"Pharmacodynamic effects of aripiprazole and ziprasidone with respect to P-glycoprotein substrate properties","volume":"46","author":"Holthoewer","year":"2013","journal-title":"Pharmacopsychiatry"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci."},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.11.55","article-title":"Relationship between P-glycoprotein and second-generation antipsychotics","volume":"12","author":"Moons","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"e01441","DOI":"10.1002\/brb3.1441","article-title":"Trend of antidepressants before, during, and after pregnancy across two decades-A population-based study","volume":"9","author":"Sun","year":"2019","journal-title":"Brain Behav."},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jad.2019.12.014","article-title":"The international prevalence of antidepressant use before, during, and after pregnancy: a systematic review and meta-analysis of timing, type of prescriptions and geographical variability","volume":"264","author":"Molenaar","year":"2020","journal-title":"J Affective Disord."},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/phar.1649","article-title":"A review of antibiotic use in pregnancy","volume":"35","author":"Bookstaver","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40262-017-0506-8","article-title":"Renal drug transporters and drug interactions","volume":"56","author":"Ivanyuk","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1128\/AAC.00771-09","article-title":"Pharmacokinetic properties of azithromycin in pregnancy","volume":"54","author":"Salman","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1128\/AAC.00717-11","article-title":"Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age","volume":"56","author":"Fischer","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1128\/AAC.02011-12","article-title":"Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy","volume":"57","author":"Matzneller","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R72-20250603","first-page":"1635","article-title":"Pharmacokinetics of azlocillin in subjects with normal and impaired renal function","volume":"38","author":"Leroy","year":"1988","journal-title":"Antimicrob Agents Chemother."},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dkaa468","article-title":"Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study","volume":"76","author":"Wu","year":"2021","journal-title":"J Antimicrob Chemother."},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2165\/00003088-198712020-00004","article-title":"Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women","volume":"12","author":"Philipson","year":"1987","journal-title":"Clin Pharmacokinet."},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/bod.2510090406","article-title":"Pharmacokinetics of cefazolin administered as a new drug delivery system in healthy volunteers","volume":"9","author":"Lanao","year":"1988","journal-title":"Biopharm Drug Dispos"},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2710.2007.00864.x","article-title":"Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women","volume":"32","author":"Popovi\u0107","year":"2007","journal-title":"J Clin Pharm Ther."},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"170.e1","DOI":"10.1016\/j.ajog.2008.08.067","article-title":"Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy","volume":"200","author":"Allegaert","year":"2009","journal-title":"Am J Obstet Gynecol."},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1128\/AAC.02613-13","article-title":"Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery","volume":"58","author":"Elkomy","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"541.e1","DOI":"10.1016\/j.ajog.2015.06.034","article-title":"Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery","volume":"213","author":"Young","year":"2015","journal-title":"Am J Obstet Gynecol."},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/bja\/aex026","article-title":"Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial","volume":"118","author":"Naik","year":"2017","journal-title":"Br J Anaesth."},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000097105","article-title":"Pharmacokinetics of oral cefatrizine in pregnant and non-pregnant women with reference to fetal distribution","volume":"22","author":"Papantoniou","year":"2007","journal-title":"Fetal Diagn Ther."},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10156-007-0539-2","article-title":"Antibacterial activity and PK\/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia","volume":"13","author":"Ohno","year":"2007","journal-title":"J Infect Chemother."},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/bcpt.13245","article-title":"Cefoperazone\/sulbactam therapeutic drug monitoring inpatients with liver cirrhosis: potential factors affecting the pharmacokinetic\/pharmacodynamic target attainment","volume":"125","author":"Dong","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/AAC.29.5.873","article-title":"Pharmacokinetics of cefotaxime, moxalactam, and cefoperazone in the early puerperium","volume":"29","author":"Charles","year":"1986","journal-title":"Antimicrob Agents Chemother."},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"777854","DOI":"10.3389\/fped.2022.777854","article-title":"Beta-lactams therapeuticmonitoring in septic children\u2013what target are we aiming for? a scoping review","volume":"10","author":"Morales Junior","year":"2022","journal-title":"Front Pediatr."},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/AAC.36.12.2652","article-title":"Pharmacokinetics and transplacental passage of imipenem during pregnancy","volume":"36","author":"Heikkila","year":"1992","journal-title":"Antimicrob Agents Chemother."},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jac\/dkn543","article-title":"Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion","volume":"63","author":"Jaruratanasirikul","year":"2009","journal-title":"J Antimicrob Chemother."},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/IDR.S150431","article-title":"Antibacterial effect evaluation of moxalactam against extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae with in vitro pharmacokinetics\/pharmacodynamics simulation","volume":"11","author":"Huang","year":"2018","journal-title":"Infect Drug Resist."},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2125.1985.tb02693.x","article-title":"Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin","volume":"19","author":"Overbosch","year":"1985","journal-title":"Br J Clin Pharmacol."},{"key":"R90-20250603","first-page":"919","article-title":"The need for adjustment of dosage regimen of penicillin V during pregnancy","volume":"81","author":"Heikkila","year":"1993","journal-title":"Obstet Gynecol."},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0301-2115(97)00150-4","article-title":"Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam combination","volume":"76","author":"Bourget","year":"1998","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijantimicag.2011.10.011","article-title":"Continuous infusion of piperacillin\/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs","volume":"39","author":"Duszynska","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"R93-20250603","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1128\/AAC.01605-15","article-title":"Artemether-lumefantrine pharmacokinetics and clinical response are minimally altered in pregnant Ugandan women treated for uncomplicated falciparum malaria","volume":"60","author":"Nyunt","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"e01140-19","DOI":"10.1128\/AAC.01140-19","article-title":"A randomized controlled trial of three-versus five-day artemether-lumefantrine regimens for treatment of uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa","volume":"64","author":"Onyamboko","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00228-006-0199-7","article-title":"The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria","volume":"62","author":"McGready","year":"2006","journal-title":"Eur J Clin Pharmacol."},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1475-2875-10-114","article-title":"Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria","volume":"10","author":"Morris","year":"2011","journal-title":"Malar J."},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1128\/AAC.00195-09","article-title":"Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria","volume":"53","author":"Tarning","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"R98-20250603","first-page":"139","article-title":"Antiretroviral therapy with efavirenz accentuates pregnancy- associated reduction of dihydroartemisinin-piperaquine exposure during malaria chemoprevention","volume":"176","author":"Kajubi","year":"2017","journal-title":"Physiol Behav."},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1128\/AAC.00154-11","article-title":"Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria","volume":"55","author":"Rijken","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R100-20250603","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/jac\/dku154","article-title":"Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso","volume":"69","author":"Valea","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1128\/AAC.00326-15","article-title":"Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women","volume":"59","author":"Benjamin","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R102-20250603","doi-asserted-by":"crossref","first-page":"e01393-18","DOI":"10.1128\/AAC.01393-18","article-title":"Modeling prevention of malaria and selection of drug resistance with different dosing schedules of dihydroartemisinin-piperaquine preventive therapy during pregnancy in Uganda","volume":"63","author":"Wallender","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00228-008-0500-z","article-title":"Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria","volume":"64","author":"Lee","year":"2008","journal-title":"Eur J Clin Pharmacol."},{"key":"R104-20250603","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1128\/AAC.01269-09","article-title":"Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy","volume":"54","author":"Karunajeewa","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R105-20250603","doi-asserted-by":"crossref","first-page":"e1002212","DOI":"10.1371\/journal.pmed.1002212","article-title":"Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta-analysis","volume":"14","author":"Hoglund","year":"2017","journal-title":"PLoS Med."},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2125.1990.tb03746.x","article-title":"Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study","volume":"30","author":"Nosten","year":"1990","journal-title":"Br J Clin Pharmacol."},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00228-005-0969-7","article-title":"The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women","volume":"61","author":"Na-Bangchang","year":"2005","journal-title":"Eur J Clin Pharmacol."},{"key":"R108-20250603","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12936-015-1049-9","article-title":"Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya","volume":"15","author":"Green","year":"2016","journal-title":"Malar J."},{"key":"R109-20250603","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1086\/503423","article-title":"Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant plasmodium falciparum malaria","volume":"42","author":"Price","year":"2006","journal-title":"Clin Infect Dis."},{"key":"R110-20250603","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bcp.12660","article-title":"Opposite malaria and pregnancy effect on oral bioavailability of artesunate\u2014a population pharmacokinetic evaluation","volume":"80","author":"Kloprogge","year":"2015","journal-title":"Br J Clin Pharmacol."},{"key":"R111-20250603","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1475-2875-10-49","article-title":"Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC","volume":"10","author":"Onyamboko","year":"2011","journal-title":"Malar J."},{"key":"R112-20250603","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/psp4.12181","article-title":"Pharmacokinetics of sulfadoxine and pyrimethamine for intermittent preventive treatment of malaria during pregnancy and after delivery","volume":"6","author":"De Kock","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R113-20250603","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1128\/AAC.00182-11","article-title":"Pharmacokinetic\/Pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization","volume":"55","author":"Nielsen","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R114-20250603","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","article-title":"BDDCS applied to over 900 drugs","volume":"13","author":"Benet","year":"2011","journal-title":"AAPS J."},{"key":"R115-20250603","first-page":"1","article-title":"The role of transporters in the pharmacokinetics of antibiotics advances in pharmacoepidemiology & drug safety","volume":"3","author":"Hua","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"R116-20250603","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/j.1875-9114.1982.tb03187.x","article-title":"A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy","volume":"2","author":"Fitzpatrick","year":"1982","journal-title":"Pharmacother J Hum Pharmacol Drug Ther."},{"key":"R117-20250603","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1128\/AAC.34.5.823","article-title":"Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin","volume":"34","author":"Barriere","year":"1990","journal-title":"Antimicrob Agents Chemother."},{"key":"R118-20250603","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/dmd.112.049569","article-title":"Organic anion transporter 3 interacts selectively with lipophilic-lactam antibiotics","volume":"41","author":"Wolman","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"R119-20250603","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1248\/bpb.34.389","article-title":"Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes","volume":"34","author":"Yamaguchi","year":"2011","journal-title":"Biol Pharm Bull."},{"key":"R120-20250603","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4081\/idr.2011.2412","article-title":"Safety, pharmacokinetics and efficacy of artemisinins in pregnancy","volume":"3","author":"Ades","year":"2011","journal-title":"Infect Dis Rep."},{"key":"R121-20250603","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/S1473-3099(18)30065-3","article-title":"Treatment of uncomplicated and severe malaria during pregnancy","volume":"18","author":"D'Alessandro","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"R122-20250603","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00228-003-0636-9","article-title":"Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data","volume":"59","author":"Li","year":"2003","journal-title":"Eur J Clin Pharmacol."},{"key":"R123-20250603","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003088-200847020-00002","article-title":"Clinical pharmacology of artemisinin-based combination therapies","volume":"47","author":"Aweeka","year":"2008","journal-title":"Clin Pharmacokinet."},{"key":"R124-20250603","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2125.2011.04103.x","article-title":"Artesunate\/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects","volume":"73","author":"McGready","year":"2012","journal-title":"Br J Clin Pharmacol."},{"key":"R125-20250603","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1128\/AAC.02595-14","article-title":"Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania","volume":"58","author":"Mosha","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R126-20250603","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1473-3099(07)70025-7","article-title":"Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance","volume":"7","author":"Ward","year":"2007","journal-title":"Lancet Infect Dis."},{"key":"R127-20250603","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1371\/journal.pmed.0050253","article-title":"A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy","volume":"5","author":"McGready","year":"2008","journal-title":"PLoS Med."},{"key":"R128-20250603","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1128\/AAC.00267-15","article-title":"Lumefantrine and desbutyl-lumefantrine population pharmacokinetic-pharmacodynamic relationships in pregnant women with uncomplicated plasmodium falciparum malaria on the Thailand-myanmar border","volume":"59","author":"Kloprogge","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R129-20250603","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdu376","article-title":"Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics","volume":"25","author":"Berveiller","year":"2014","journal-title":"Ann Oncol."},{"key":"R130-20250603","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/CCO.0000000000000386","article-title":"Cancer in pregnancy: safety and efficacy of systemic therapies","volume":"29","author":"Boere","year":"2017","journal-title":"Curr Opin Oncol."},{"key":"R131-20250603","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdz228","article-title":"Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting","volume":"30","author":"Amant","year":"2019","journal-title":"Ann Oncol."},{"key":"R132-20250603","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/annonc\/mdu140","article-title":"Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel","volume":"25","author":"van Hasselt","year":"2014","journal-title":"Ann Oncol."},{"key":"R133-20250603","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40262-020-00961-4","article-title":"Population pharmacokinetics of docetaxel, paclitaxel, doxorubicin and epirubicin in pregnant women with cancer: a study from the international network of cancer, infertility and pregnancy (INCIP)","volume":"60","author":"Janssen","year":"2021","journal-title":"Clin Pharmacokinet."},{"key":"R134-20250603","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00280-014-2406-z","article-title":"Pharmacokinetics of doxorubicin in pregnant women","volume":"73","author":"Ryu","year":"2014","journal-title":"Cancer Chemother Pharmacol."},{"key":"R135-20250603","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00280-017-3511-6","article-title":"Pharmacokinetics of dacarbazine (DTIC) in pregnancy","volume":"81","author":"Kantrowitz-gordon","year":"2018","journal-title":"Cancer Chemother Pharmacol."},{"key":"R136-20250603","first-page":"278","article-title":"Chemotherapy during pregnancy: pharmacokinetics and impact on foetal neurological development","volume":"2","author":"Van Calsteren","year":"2010","journal-title":"Facts Views Vis Obgyn"},{"key":"R137-20250603","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3109\/00016349.2010.512070","article-title":"Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study","volume":"89","author":"Van Calsteren","year":"2010","journal-title":"Acta Obstet Gynecol Scand."},{"key":"R138-20250603","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2165\/00003088-199426060-00002","article-title":"Clinical pharmacokinetics of epirubicin","volume":"26","author":"Robert","year":"1994","journal-title":"Clin Pharmacokinet."},{"key":"R139-20250603","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/138920010791110890","article-title":"Pharmacogenetics of target genes across doxorubicin disposition pathway: a review","volume":"11","author":"Lal","year":"2010","journal-title":"Curr Drug Metab."},{"key":"R140-20250603","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00265388","article-title":"Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules","volume":"9","author":"Breithaupt","year":"1982","journal-title":"Cancer Chemother Pharmacol."},{"key":"R141-20250603","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2165\/00003088-199121040-00002","article-title":"Clinical pharmacokinetics of carboplatin","volume":"21","author":"van der Vijgh","year":"1991","journal-title":"Clin Pharmacokinet."},{"key":"R142-20250603","first-page":"2192","article-title":"Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1","volume":"5","author":"Reid","year":"1999","journal-title":"Clin Cancer Res."},{"key":"R143-20250603","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2125.2007.02886_4.x","article-title":"Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: a study by the EORTC-PAMM-NDDG","volume":"63","author":"Joerger","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"R144-20250603","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.breast.2009.05.004","article-title":"Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet)","volume":"18","author":"Leonard","year":"2009","journal-title":"Breast"},{"key":"R145-20250603","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cgh.2018.11.055","article-title":"Outcomes of pregnancy in recipients of liver transplants","volume":"17","author":"Kamarajah","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R146-20250603","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/lt.24182","article-title":"Outcomes of pregnancy following liver transplantation: the King's College Hospital experience","volume":"21","author":"Westbrook","year":"2015","journal-title":"Liver Transpl."},{"key":"R147-20250603","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R148-20250603","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/FTD.0b013e3182708edf","article-title":"Pharmacokinetics of tacrolimus during pregnancy","volume":"34","author":"Zheng","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R149-20250603","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cgh.2020.09.021","article-title":"Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis","volume":"20","author":"Nielsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R150-20250603","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/2050640620964619","article-title":"Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease","volume":"9","author":"Gri\u0161i\u0107","year":"2021","journal-title":"United Eur Gastroenterol J."},{"key":"R151-20250603","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough Concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"R152-20250603","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and\u00a0Adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R153-20250603","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1472-8206.2007.00504.x","article-title":"Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms","volume":"21","author":"Op den Buijsch","year":"2007","journal-title":"Fundam Clin Pharmacol."},{"key":"R154-20250603","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1111\/j.1600-6143.2005.01091.x","article-title":"Effect of pregnancy on long-term kidney function in renal transplant recipients treated with cyclosporine and with azathioprine","volume":"5","author":"Fischer","year":"2005","journal-title":"Am J Transplant."},{"key":"R155-20250603","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40262-018-0712-z","article-title":"Pharmacokinetics of hydroxychloroquine in pregnancies with rheumatic diseases","volume":"58","author":"Balevic","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"R156-20250603","doi-asserted-by":"crossref","first-page":"621247","DOI":"10.3389\/fphar.2021.621247","article-title":"Biologics during pregnancy and breastfeeding among women with rheumatic diseases: safety clinical evidence on the road","volume":"12","author":"Beltagy","year":"2021","journal-title":"Front Pharmacol."},{"key":"R157-20250603","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2017.07.031","article-title":"American gastroenterological association institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases","volume":"153","author":"Vande Casteele","year":"2017","journal-title":"Gastroenterology"},{"key":"R158-20250603","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/apt.14040","article-title":"The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease","volume":"45","author":"Seow","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"R159-20250603","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ecco-jcc\/jjy058","article-title":"Anti-TNF levels in cord blood at birth are associated with anti-TNF type","volume":"12","author":"Kanis","year":"2018","journal-title":"J Crohns Colitis"},{"key":"R162-20250603","doi-asserted-by":"crossref","first-page":"687978","DOI":"10.3389\/fped.2021.687978","article-title":"Physiologically based pharmacokinetics model in pregnancy: a regulatory perspective on model evaluation","volume":"9","author":"Coppola","year":"2021","journal-title":"Front Pediatr."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:26:03Z","timestamp":1748957163000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":152,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001039","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"2022-02-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}